Comparison of changes in ferritin, LIC, and the iron excretion-intake ratio by dose
LIC, mg Fe/g dw (median deferasirox and deferoxamine doses, mg/kg/d) . | Change in serum ferritin, μg/L, mean ± SD . | Change in LIC, mg Fe/g dw, mean ± SD . | Iron excretion-intake ratio, mean ± SD . |
|---|---|---|---|
| 3 mg Fe/g dw or less (5/30)* | |||
| Deferasirox | +1189 ± 700 | +4.8 ± 3.77 | 0.58 ± 0.328 |
| Deferoxamine | +211 ± 459 | +0.5 ± 1.11 | 0.95 ± 0.101 |
| More than 3 mg Fe/g dw to 7 mg Fe/g dw (10/35)† | |||
| Deferasirox | +833 ± 817 | +3.8 ± 3.85 | 0.67 ± 0.365 |
| Deferoxamine | +32 ± 585 | 0.0 ± 2.36 | 0.98 ± 0.217 |
| More than 7 mg Fe/g dw to 14 mg Fe/g dw (20/41)‡ | |||
| Deferasirox | -36 ± 721 | -0.4 ± 4.70 | 1.02 ± 0.398 |
| Deferoxamine | -364 ± 614 | -1.9 ± 2.93 | 1.13 ± 0.241 |
| More than 14 mg Fe/g dw (30/51)§ | |||
| Deferasirox | -926 ± 1416 | -8.9 ± 8.07 | 1.67 ± 0.716 |
| Deferoxamine | -1003 ± 1428 | -6.4 ± 6.93 | 1.44 ± 0.596 |
LIC, mg Fe/g dw (median deferasirox and deferoxamine doses, mg/kg/d) . | Change in serum ferritin, μg/L, mean ± SD . | Change in LIC, mg Fe/g dw, mean ± SD . | Iron excretion-intake ratio, mean ± SD . |
|---|---|---|---|
| 3 mg Fe/g dw or less (5/30)* | |||
| Deferasirox | +1189 ± 700 | +4.8 ± 3.77 | 0.58 ± 0.328 |
| Deferoxamine | +211 ± 459 | +0.5 ± 1.11 | 0.95 ± 0.101 |
| More than 3 mg Fe/g dw to 7 mg Fe/g dw (10/35)† | |||
| Deferasirox | +833 ± 817 | +3.8 ± 3.85 | 0.67 ± 0.365 |
| Deferoxamine | +32 ± 585 | 0.0 ± 2.36 | 0.98 ± 0.217 |
| More than 7 mg Fe/g dw to 14 mg Fe/g dw (20/41)‡ | |||
| Deferasirox | -36 ± 721 | -0.4 ± 4.70 | 1.02 ± 0.398 |
| Deferoxamine | -364 ± 614 | -1.9 ± 2.93 | 1.13 ± 0.241 |
| More than 14 mg Fe/g dw (30/51)§ | |||
| Deferasirox | -926 ± 1416 | -8.9 ± 8.07 | 1.67 ± 0.716 |
| Deferoxamine | -1003 ± 1428 | -6.4 ± 6.93 | 1.44 ± 0.596 |
For patients with LIC levels of 3 mg Fe/g dw or less treated with deferasirox, n = 15; for those treated with deferoxamine, n = 13.
For patients with LIC levels above 3 but not more than 7 treated with deferasirox, n = 73 (measurements of change in LIC and iron excretion-intake ratio reflect n = 68); for those treated with deferoxamine, n = 77 (measurements of change in LIC and iron excretion-intake ratio reflect n = 75).
For patients with LIC levels above 7 but not more than 14 treated with deferasirox, n = 80 (measurements of change in LIC and iron excretion-intake ratio reflect n = 77); for those treated with deferoxamine, n = 89 (measurements of change in LIC and iron excretion-intake ratio reflect n = 87).
For patients with LIC levels above 14 treated with deferasirox, n = 115 (measurements of change in LIC and iron excretion-intake ratio reflect n = 108); for those treated with deferoxamine, n = 101 (measurements of change in LIC and iron excretion-intake ratio reflect n = 98).